Cronos Group Inc.
NASDAQ:CRONDrug Manufacturers - Specialty & Generic
-$0.02 today
- Market cap
- $1.16B
- Beta
- 1.25
- P/E (TTM)
- -488.3
- EPS (TTM)
- -$0.01
Volume 1.13M
Average 1.51M
CRON Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Cronos Group Inc.NASDAQ: CRON
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$823.24M, compared with -$796M a year earlier.
Context
- Net debt amounted to 70.0% of total assets at the end of Q1 FY2026, up 1.0 pp from a year earlier.
- Net debt grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -3.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (790.29M) USD
- Year-over-year change
- +7.8%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (790.29M) | +7.8% |
| FY2024 | 2024-12-31 | (856.79M) | -28.5% |
| FY2023 | 2023-12-31 | (666.74M) | +12.4% |
| FY2022 | 2022-12-31 | (760.77M) | +13.3% |
| FY2021 | 2021-12-31 | (877.17M) | — |
Net Debt vs competitors
How CRON compares with its peers on the latest reported figures
- CRON's Mar 2026 net debt of -$823.24M is the lowest of the 11 companies compared; the peer median is $2.97M.
- Its year-over-year change of -3.4% is the 2nd highest of 11, against a peer median of -26.1%.
- Net debt amounts to 70.0% of total assets for CRON, versus a peer median of 26.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $1.17B | -12.6% | -2.8% | 113.9% | |
| Mar 2026 | $539.41M | -27.9% | +8.8% | 32.7% | |
| Mar 2026 | $515.2M | +9.7% | — | 31.3% | |
| Mar 2026 | $266.87M | -24.4% | -23.4% | 22.1% | |
| Jun 2026 | $20.55M | -12.5% | +186.4% | 2.8% | |
| Mar 2026 | -$14.6M | -104.1% | — | 4.8% | |
BBOTBridgeBio Oncology Therapeutics Inc. | Mar 2026 | -$50.01M | -112.2% | — | 12.0% |
| Mar 2026 | -$56.37M | -12.1% | — | 49.3% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | -$67.25M | -35.1% | — | 13.5% |
| Aug 2026 | -$654.91M | -2883.4% | — | 54.8% | |
| Mar 2026 | -$823.24M | -3.4% | — | 70.0% | |
| Peer median (excluding CRON) | $2.97M | -26.1% | +3.0% | 26.7% | |
Competitors are the stored peer set for CRON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 886.97M | 764.64M | 669.29M | 858.81M | 791.79M |
| Short-term Investments | 117.68M | 113.08M | 192.24M | 0 | 40M |
| Net Receivables | 33.29M | 31.29M | 35.88M | 29.77M | 57.2M |
| Inventory | 32.8M | 37.56M | 30.5M | 33.15M | 46.75M |
| Other Current Assets | 0 | 7.11M | 5.41M | 14.39M | 8.34M |
| Total Current Assets | 1.08B | 960.16M | 933.31M | 936.11M | 944.09M |
| Property, Plant & Equipment (Net) | 82.95M | 62.83M | 60.82M | 134.58M | 147.29M |
| Goodwill | 1.1M | 1.03M | 1.06M | 63.45M | 66.48M |
| Intangible Assets | 18.08M | 26.7M | 21.08M | 11.13M | 8.89M |
| Long-term Investments | 135.16M | 89.75M | 54.74M | 2.81M | 7.66M |
| Tax Assets | 0 | 0 | 226K | 2.57M | 1.89M |
| Other Non-current Assets | 80.74M | 72.54M | 69.04M | 15.53M | 20.85M |
| Total Non-current Assets | 318.02M | 252.85M | 206.96M | 230.07M | 253.05M |
| Total Assets | 1.4B | 1.21B | 1.14B | 1.17B | 1.2B |
| Account Payables | 11.11M | 11.16M | 12.13M | 16.97M | 11.64M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 3.59M | 37.09M | 11.76M | 11.84M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 14.38M | 15K | 102K | 40K | 20.11M |
| Total Current Liabilities | 54.37M | 68.12M | 41.4M | 49.7M | 48.19M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 81K | 0 | 181K | 3.56M | 4.09M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 1.91M | 1.38M | 1M | 1.07M | 733K |
| Total Non-current Liabilities | 9.09M | 3.93M | 2.74M | 5.63M | 5.99M |
| Total Liabilities | 63.46M | 72.05M | 44.14M | 55.33M | 54.18M |
| Common Stock | 595.5M | 611.32M | 662.17M | 669.88M | 661.78M |
| Retained Earnings | 659.42M | 490.68M | 416.72M | 457.71M | 447.76M |
| Accumulated OCI | 49.87M | (797K) | 20.68M | (63.53M) | (16.84M) |
| Other Stockholders Equity | 0 | 0 | (48.45M) | 0 | 0 |
| Minority Interest | (2.97M) | (2.92M) | (3.45M) | 46.92M | 49.06M |
| Total Equity | 1.33B | 1.14B | 1.1B | 1.11B | 1.14B |
| Total Debt | 9.81M | 3.88M | 2.55M | 2.02M | 1.51M |
| Net Debt | (877.17M) | (760.77M) | (666.74M) | (856.79M) | (790.29M) |
Cronos Group Inc.
NASDAQ:CRON
Intrinsic Alpha fair value
Locked
Current Price
$3.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.